Search Within
Applied Filters:
Keyword:'y0000440'
Showing 1-25 of 25 results for "
y0000440
" within PapersSort by Relevance
Richard M Hoglund et al.
British journal of clinical pharmacology, 79(4), 636-649 (2014-10-10)
Drug-drug interactions between antimalarial and antiretroviral drugs may influence antimalarial treatment outcomes. The aim of this study was to investigate the potential drug-drug interactions between the antimalarial drugs, lumefantrine, artemether and their respective metabolites desbutyl-lumefantrine and dihydroartemisinin, and the HIV
Rosario Palacios et al.
Expert review of anti-infective therapy, 4(6), 965-971 (2006-12-22)
There are currently several suitable and different antiretroviral regimens to start highly active antiretroviral therapy (HAART), and many clinicians and patients prefer once-daily therapy. The efficacy and potency of efavirenz (EFV) has been established in many clinical trials and cohort
Tenofovir and didanosine: a dangerous liaison.
Laura Waters et al.
The AIDS reader, 15(8), 403-406 (2005-08-23)
J J McGowan et al.
Reviews of infectious diseases, 12 Suppl 5, S513-S520 (1990-07-01)
AIDS has remained a significant and worsening medical problem since its first description as a new clinical entity in 1981. In the past 6 years, substantial progress has been made in the chemotherapy for this disease; such progress is likely
William R Birmingham et al.
Nature chemical biology, 10(5), 392-399 (2014-03-25)
Concatenation of engineered biocatalysts into multistep pathways markedly increases their utility, but the development of generalizable assembly methods remains a major challenge. Herein we evaluate 'bioretrosynthesis', which is an application of the retrograde evolution hypothesis, for biosynthetic pathway construction. To
Fanconi syndrome and nephrogenic diabetes insipidus associated with didanosine therapy in HIV infection: a case report and literature review.
Géraldine D'Ythurbide et al.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 22(12), 3656-3659 (2007-10-02)
Marco Bongiovanni et al.
Current medicinal chemistry, 13(23), 2789-2793 (2006-11-01)
Nucleoside reverse transcriptase inhibitors (NRTI) are essential components of highly active antiretroviral treatment (HAART). Although several combinations can be used as NRTI backbones, not all are associated with good virological and/or immunological results. In particular, some NRTI combinations should be
J Darbyshire et al.
The Cochrane database of systematic reviews, (2)(2), CD002038-CD002038 (2000-05-05)
Zidovudine (AZT) monotherapy was the first antiretroviral drug to be tested widely. The next two drugs to be developed were didanosine (ddI) and zalcitabine (ddC). To assess the effects of zidovudine (AZT), zidovudine plus didanosine (ddI) and zidovudine plus zalcitabine
Down-regulation of mitochondrial thymidine kinase 2 and deoxyguanosine kinase by didanosine: implication for mitochondrial toxicities of anti-HIV nucleoside analogs.
Sun R, Eriksson S, and Wang L
Biochemical and Biophysical Research Communications, 450(2), 1021-1026 (2014)
Santiago Moreno et al.
Drugs, 67(10), 1441-1462 (2007-06-30)
Didanosine, which is a synthetic nucleoside analogue intracellularly phosphorylated to the active metabolite, inhibits the activity of HIV-1 reverse transcriptase by competing with the natural substrate. Currently, didanosine is mainly provided as an enteric-coated capsule. In vitro, the molecule is
R B Pollard
AIDS (London, England), 14(16), 2421-2428 (2000-01-11)
Factors affecting patient adherence to therapy, such as frequent daily dosing and complex dosing schedules, are widely understood to be key obstacles to the durability of effective anti-HIV therapy. Didanosine, a nucleoside analogue reverse transcriptase inhibitor (NRTI) that is a
Masahiko Okiyama et al.
Nihon yakurigaku zasshi. Folia pharmacologica Japonica, 120(2), 115-122 (2002-08-22)
An active metabolite, ddATP, of didanosine that is an analogue of purine-nucleoside (a component of nucleic acid) was known to inhibit the activity of DNA polymerase for E. coli. In 1985, Dr. Michiya et al. of NCI reported that didanosine
Patrice K Nicholas et al.
The Journal of the Association of Nurses in AIDS Care : JANAC, 25(4), 318-329 (2014-04-05)
Peripheral neuropathy is a common and vexing symptom for people living with HIV infection (PLWH). Neuropathy occurs in several different syndromes and is identified in the literature as distal sensory polyneuropathy or distal sensory peripheral neuropathy. More recently, the HIV
C M Perry et al.
Drugs, 52(6), 928-962 (1996-12-01)
Didanosine is a dideoxynucleoside analogue, which is phosphorylated to the active metabolite dideoxyadenosine triphosphate (ddATP) intracellularly. At therapeutic concentrations, ddATP inhibits HIV replication by inhibiting HIV reverse transcriptase. Didanosine is established as a first-line treatment for patients with HIV disease
I Sanne et al.
International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 5(1), 43-48 (2001-04-04)
Effective antiretroviral therapy remains beyond the reach of most human immunodeficiency virus (HIV)-infected persons living in the third world because of its tremendous cost. The cancer drug, hydroxyurea, inhibits HIV-1 replication in vitro and, when combined with didanosine (ddI), results
M Youle
Antiviral therapy, 3 Suppl 4, 35-37 (2000-03-21)
The current focus on simplifying treatment regimens for patients with human immunodeficiency virus (HIV) infection has contributed to the interest in once-daily therapy. The triphosphate of didanosine (2',3'-dideoxyinosine or DDI) has a long intracellular half-life, which supports the use of
J Darbyshire et al.
The Cochrane database of systematic reviews, (3)(3), CD002038-CD002038 (2000-07-25)
Zidovudine (AZT) monotherapy was the first antiretroviral drug to be tested widely. The next two drugs to be developed were didanosine (ddI) and zalcitabine (ddC). To assess the effects of zidovudine (AZT), zidovudine plus didanosine (ddI) and zidovudine plus zalcitabine
Patricia Pecora Fulco et al.
The Annals of pharmacotherapy, 37(9), 1325-1328 (2003-08-19)
To evaluate the pharmacokinetic interaction between tenofovir and didanosine when used in combination as a highly active antiretroviral therapy regimen. Literature retrieval was accessed through MEDLINE (1966-January 2003) using the terms tenofovir and didanosine. Abstracts from recent meetings, including the
B G Gazzard et al.
Antiviral therapy, 2(3), 135-147 (1997-07-01)
Large-scale clinical end point studies comparing antiretroviral therapy with zidovudine alone, didanosine alone, and zidovudine combined with didanosine indicate that both didanosine alone and zidovudine/didanosine provide a better clinical outcome than zidovudine alone in patients with human immunodeficiency virus (HIV)
Severe toxicity associated with the combination of tenofovir and didanosine: case report and review.
M Masiá et al.
International journal of STD & AIDS, 16(9), 646-648 (2005-09-24)
The combination of tenofovir and didanosine results in an increase in the didanosine plasma exposure and might augment the risk for didanosine toxicity. Although pharmacokinetic studies support a didanosine dose reduction to 250 mg when used concurrently with tenofovir in
Toxic interaction of didanosine and acetaminophen leading to severe hepatitis and pancreatitis: a case report and review of the literature.
J C Lederman et al.
The American journal of gastroenterology, 96(12), 3474-3475 (2002-01-05)
Hui-Min Chang et al.
Japanese journal of infectious diseases, 65(1), 61-65 (2012-01-26)
Noncirrhotic portal hypertension (NCPH) has recently been reported as a liver complication in human immunodeficiency virus (HIV)-infected patients and has been found to be associated with exposure to didanosine. Here, we describe the case of an HIV-infected patient with portal
David A Cooper
Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002), 1(1), 15-25 (2003-08-29)
Didanosine (ddl) has been a cornerstone of HIV management since it was made available in October 1991. Didanosine was originally introduced as an alternative to zidovudine (ZDV) for patients who were intolerant of ZDV or experienced disease progression during ZDV
C M Perry et al.
Drugs, 58(6), 1099-1135 (2000-01-29)
Didanosine, like zidovudine, stavudine and lamivudine, is a nucleoside analogue reverse transcriptase inhibitor (NRTI). In the target cell for HIV, didanosine is converted to its active moiety, dideoxyadenosine-5'-triphosphate (ddATP), which inhibits HIV reverse transcriptase and terminates viral DNA growth. It
Target cell availability and the successful suppression of HIV by hydroxyurea and didanosine.
R J De Boer et al.
AIDS (London, England), 12(13), 1567-1570 (1998-10-09)
Page 1 of 1
Page 1 of 1